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Abstract
Purpose: Xerostomia is a well known complication of radiation for head and neckcancer. It causes significant impairment of Quality Of Life (QOL).Comprehensiveassessment is possible with the help of scintigraphy, Dose-volume histogram(DVH) parameters as well as QOL questionnaire. Methods: Thirty patients of headand neck cancer undergoing radiation were assessed for xerostomia. Scintigraphicassessment of parotid gland function was done before and at six weeks afterradiation. QOL questionnaire was administered before, during, and at six weeksafter radiation as well as at two years of follow up. Dose received by parotids werecorrelated with scintigraphic and QOL outcomes. Results: Mean parotid glandvolume and dose received were 24.9 cc and 45.3 Gy respectively. Mean SalivaryExcretion Factor (SEF) decreased from 54.1 to 12 at six weeks after radiation. QOLscores worsened from first week (mean value: 2.37) of radiotherapy (RT) to fourthweek (mean value: 15.50, p < 0.0000) , remained same till completion of RT (meanvalue: 17.57, p = 0.1063) and at six weeks after radiation (mean value:16.10, p =0.2519 ). There was a significant decrease in QOL scores between post RT sixweeks versus two years follow up (p < 0.0000). Mean parotid dose and QOL scorescorrelated at six weeks (p < 0.0000), whereas no correlation was found betweenSEF and QOL. Conclusion: Comprehensive assessment of parotid gland functionwith Scintigraphy, QOL questionnaire and its correlation with dose volumeparameters is helpful in quantifying xerostomia. Even though radiation inducedxerostomia persisted for a long time after radiation, it did not translate todecreased QOL.
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1. IntroductionOver 200,000 cases of head and neck cancers occur eachyear in India accounting for 30% of all cancers in malesand 11 to 16% of all cancers among females. More thanhalf of them present with locally advanced disease.1Over the years, the treatment of head & neck cancer haschanged from radical surgery to organ or functionpreserving multimodality approach. Radiation has animportant role in definitive as well as adjuvant context.Xerostomia is one of the most important sequelae ofradiation, which interferes with the Quality Of Life(QOL) of the patient. Exact incidence is unclear sincegrading; definition and radiation fields vary, but rangesfrom 60% to 100%.2 It lasts for up to several months
to years and may or may not recover, depending on thevolume of salivary glands irradiated, the total radiationdose and individual patient variation.3With the adventof computed tomography (CT) based planning,quantification of dose received by parotid is possible.The different ways of assessing parotid gland functionare scintigraphy4, QOL questionnaire5, 6, 7 among manyothers. Although enough data is available on each ofthese, a combination of these would be ideal and thedata is sparse.8 In this study, an attempt is made tocorrelate dose volume characteristics of parotid withsubjective as well as objective assessment of xerostomia.
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2. Methods and MaterialsThis prospective study was conducted betweenDecember 2011 & May 2013 in which thirty patients ofhead and neck cancer were included. Sample size wasdecided in consultation with the biostatistician, with apower of 80% & alpha error of 5%. Inclusion criteriawere biopsy proven patients undergoing definitive oradjuvant radiation with both parotids in the field ofirradiation. Patients who had tumors of parotid, historyof drug intake causing xerostomia, previous parotidsurgery and earlier irradiation were considered asexclusion criteria.
Table 1: Questionnaire to assess xerostomiaQuestions No Mild Severe1 Do you have pain inyour mouth?2 Do you have anydryness in yourmouth?3 Do you have trouble ineating?4 Do you have  problemswallowing liquids?5 Do you have problemchewing solid food?6 Do you have problemswallowing solid food ?7 Have you choked whenswallowing?8 Do you have stickysaliva?9 Do you have problemwith your sense oftaste?10 Do you have problemwith your sense ofsmell?11 Do you have troubleenjoying your meals ?12 Do you have cough?13 Do you have trouble intalking?Following informed consent and investigations, allpatients were treated as per the department protocol.This included immobilization, CT simulation with 3 - 5mm cuts, contouring and treatment either with 3dimensional conformal radiation therapy (3DCRT) orintensity modulated radiation therapy (IMRT). Forpatients with adjuvant intent, a dose of 60 Gy and forpatients with definitive intent 66 - 70 Gy with two Gyper fraction over six to seven weeks was given. Dosereceived by parotids was obtained from dose volumehistogram (DVH) parameters. Patients also receivedneoadjuvant or concurrent cisplatin chemotherapy.Scintigraphic evaluation of parotid was done prior toradiation and at six weeks after completion.
Table 2: Patient and treatment characteristicsVariable At 6 weeks postRT (%) At 2 yearfollow up (%)SexMale 23 (77) 11 (91.7)Female 7 (23) 1 (8.3)Age31-40 3 (10) 1 (8.3)41-50 13(43) 6 (50)51-60 7 (23) 1 (8.3)61-70 7 (23) 4 (33.3)Site of malignancyNasopharynx 2 (7) 1 (8.3)Oral cavity 7 (23) 2 (16.7)Oropharynx 6 (10) 4 (33.3)Hypopharynx 7 (23) 2 16.7)Larynx 5 (17) 2 (16.7)Others 3 (10) 1 (8.3)Treatment givenAdjuvant RT CT 4 (13) 1 (8.3)Radical RT CT 26 (87) 11 (91.7)NACT 5 (16.7)Radiation techniqueIMRT 7 (23) 5 (42)3DCRT 21(70) 7 (58)Conventional 2 (7) 0Maximal uptake of the tracer without stimulus (a) andafter stimulation with lemon juice (b) were recorded ascounts per second (ct/s). Saliva Excretion Factor (SEF)was calculated using equation (a - b) / a.4 SEF ratio wascalculated by dividing SEF at post RT six weeks with SEFat baseline. To assess QOL associated with xerostomia,the most widely used questionnaire is QLQ - C30 and theQLQ – H & N35. But, in a country like ours with lot ofdiversity in language, culture and educational levels,such a valid questionnaire which can uniformly reflectQOL is challenging. Hence, a modified version similar toBenjamin et al.9 was used to assess QOL weekly duringRT, at six weeks post RT and at two years aftercompletion of radiation (Table 1).
2.1 Statistical AnalysisThe statistical software IBM SPSS 16 and 20 were usedfor analysis of the data. Paired t-test was used to find thesignificance of study parameters on continuousmeasurements and QOL scores across time. Unpaired t -test was used to test for significance betweenindependent samples like right and left parotid glands.Mann - Whitney U test was used to find any differencebetween technique and QOL scores at two years followup. Karl Pearson’s correlation coefficient was used tofind correlations between the various scintigraphicmeasures, QOL scores and parotid gland doses. P - valuelower than or equal to the significance level of 5% wasconsidered as statistically significant.
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Table 3: Change in scintigraphic measures with RTChange in aat 6 weeks after RTTime Mean SD Meandifference SD %of change Paired t P valueBaseline 2921.85 1528.15 945.69 930.07 32.37 7.8102 0.0000Post RT 1976.15 1195.32 Change in bat 6 weeks after RTTime Mean SD Meandifference SD %of change Paired t P valueBaseline 1244.07 569.82 -500.39 991.32 -40.22 -3.8772 0.0003Post RT 1744.46 1068.45 Change in SEF 6 weeks after RTTime Mean SD Meandifference SD %of change Paired t P valueBaseline 54.06 16.09 42.05 19.10 77.79 16.9093 0.0000Post RT 12.01 9.39
Figure 1: Graph showing correlation of Post RT SEF with Mean Parotid Dose. SEF reduced from 54.06 to 12.01 indicating77.79% reduction following radiation. (r = -0.3113, p = 0.0163)
Figure 2: Graph showing correlation of SEF ratio with Mean Parotid Dose. SEF ratio in our study was 24.8 indicating the parotidwere functioning at 75% of their initial activity post irradiation (r = -0.3730, p = 0.0036).
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3. ResultsA total of 30 patients of head & neck cancer wereaccrued and the study population included 23 (77%)men and seven (23%) women. The age of the patientsranged from 33 to 70 years with a median of 49.5 years.There was an equal distribution between oral cavity,oropharynx and hypopharynx. Out of 30 patients, fourpatients underwent surgery and were treated withadjuvant radiation. Two patients were carcinoma tongueand underwent wide local excision and neck dissection.One patient had metastasis of unknown origin andunderwent modified radical neck dissection while thefourth patient underwent R2 resection for middle earcarcinoma. Five patients received three cycles ofcisplatin based neo adjuvant chemotherapy followed bydefinitive RT. Out of 30 patients, 21 were treated with3DCRT, seven with IMRT and two with conventionaltechnique (Table 2). At two years follow up out of 30patients, 12 were alive for analysis. The mean dosereceived by the parotid glands was 45.3 Gy, rangingfrom 16.4 Gy to 72 Gy without any variation between thesides. The mean parotid gland volume was 24.9 cc withno significant variation between the sides. Inscintigraphy the mean maximal uptake of the tracerprior to RT ranged from 789 ct/s to 7980 ct/s with amean of 2921 ct/s with no significant differencesbetween the two sides. This uptake dropped to 1976ct/s post RT. The post stimulus nadir, b, prior to RTranged from 304 ct/s to 2890 ct/s with a mean of 1244ct/s, which has become 1744 ct/s post radiation. TheSEF value calculated from a and b is 54.1 with StandardDeviation (SD) of 16.1. The SEF has come down to 12with a SD of 12 at six weeks post RT. The change in SEF
six weeks post RT is 77.79% which is statisticallysignificant (p = 0.0000) (Table 3).
3.1 Correlation of scintigraphy with dose and
volumeThe post RT SEF was significantly correlated with meanparotid dose (r = - 0.3113, p = 0.0163) (Figure 1) but notwith mean parotid gland volume. Significant correlationwas also observed between the SEF ratio at six weeksand mean parotid gland dose (r = - 0.3730, p = 0.0036)(Figure 2). No significant correlation was found betweenthe scintigraphic measures a, b, Baseline SEF, SEFchange and mean parotid gland dose.
3.2 Correlation of QOL scores with dose and
volumeQOL scores worsened significantly from the first week ofRT to fourth week (p = 0.0000) and remained same withno statistically significant change till completion of RT (p= 0.1063), post RT six weeks (p = 0.2519) and improvedat two years follow up. There is a significant decrease inQOL scores between week seven of RT versus two yearfollow up (p = 0.0000) and post RT six weeks versus twoyear follow up (p = 0.0000) (Figures 3 & 4). There is nostatistically significant difference between the tworadiation techniques. (p = 0.7443).The mean parotid dose and QOL are significantlycorrelated at six weeks (r = 0.3116, p = 0.0004) (Figure5). No significant correlation was found between thepost RT SEF, SEF change or SEF ratio with QOL scores atsix weeks.
Figure 3: Bar diagram showing QOL scores of twelve patients. There was a significant decrease in QOL scores between postRT six weeks versus two years follow up (p = 0.0000)
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Figure 4: Line diagram showing mean QOL score with time
Figure 5: Correlation of QOL at six weeks with mean parotid dose (r = 0.3116)
4. DiscussionThe present study was designed to correlate dosevolume parameters of parotid gland with scintigraphyobjectively as well as with QOL questionnaire in headand neck cancer patients receiving RT. Majority of thepatients in the present study belonged to the age groupof 40 - 60 years, mean age being 51.8 years (range 33 -70 years). In a similar study by Roesink et al.4 the meanage was 57 years which consisted of elderly populationcompared to our study. The mean volume of parotidgland was 23cc (SD 8), which is comparable to 24.9cc(SD 8.7), in a study by Van Rij et al.10 The volume of theright and left parotid glands were found to be similar.
The mean dose of radiation received by parotid glandswas 45.3 Gy (SD 14.4) across all techniques. The meanparotid dose in those treated with IMRT was 30.8 Gy,which is similar to the 30.02 Gy by Chao et al.11 thoughmarginally higher compared to 28 Gy by Van Rij et al.10who studied the xerostomia related QOL in patientstreated with parotid sparing IMRT. The mean parotiddose using 3DCRT technique by Chao et al.11 rangedfrom 40Gy to 44.5 Gy (SD 14) when compared to dose inour study which was 49.44 Gy (SD 13.4). This differencemight be because of the differences in the doseprescription, as majority of the cases in their trial werepost - operative, treated to a dose of 60Gy while in ourstudy most of the patients were treated with definitiveRT to a dose of 66 - 70Gy. A well - known study byEmami et al. suggested TD 5 / 5 of 32 Gy and TD 50 / 5
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of 46 Gy for more than 2 / 3 parotid irradiation withsevere xerostomia as an endpoint. As per quantec data,mean parotid dose  of 25 Gy is associated with minimalgrade four xerostomia.12Ours is an observational studyand no efforts were done to spare the parotid glands.Scintigraphy was performed once at baseline and onceat six weeks post RT. The mean maximal uptake of theparotid glands before RT was 3329 ± 1675 counts persecond (ct / s) (range, 914 –10,656) in a trial by Roesink
et al. studying the early and late parotid gland functionusing scintigraphy.4 The same in our study was found tobe 2922 ± 1528 ct / s (range, 789 - 7980). The samewide range of maximal uptake across different parotidglands was reflected in our study also.The SEF was 54.06 (SD 16) prior to RT, which meansthat more than half of the accumulated activity in theparotid gland was excreted out on stimulation. This issimilar to 48 - 53.5% observed in other studies.5, 13 Thisfactor reduced to 12% (SD 9.4) after six weeks post RTwhich relates to a 77% reduction in the gland’s ability toeject the accumulated activity which is significant. It was10.7% at the end of one month as noted by Hsiung et
al.13, while it was 18.7 (SD 20.1) at six weeks by Roesink
et al.4 Though the former study had results similar toours, the difference with the latter study might bebecause of the large spread of data with wide SD. Theother reason could be the lesser mean dose of 33 Gy tothe parotids in their patients.The ratio obtained between the initial and the post RTSEF explains the proportion of functional salivary glandfunction post RT. The mean SEF ratio is 24.8 in ourstudy, indicating the parotid were functioning at 75% oftheir initial activity post irradiation. Considering SEFratio limit of 45% to assess for toxicity as suggested byRoesink et al.4, at six weeks post RT 86.4% of 59evaluated parotid glands had significant loss of function.This is similar to 88% in their study. The SEF ratio alsocorrelated with the mean parotid dose. QOLquestionnaire showed a significant worsening right fromthe first week of RT indicating the acute component ofparotid gland’s response. The change in scores wasmaximum from second to fourth week and by fifth weekhad reached a peak with no significant worsening afterthat. We found that there was no significant difference inthe scores between fourth week of radiation and sixweeks following RT. This can probably be explained bythe pain component due to the mucositis which peaksduring fourth to fifth week of RT dominating thepatients concern after fourth week. The mucositisreduces significantly by sixth week post RT and leavesthe patient with dryness of mouth as a significantmorbidity. Lent soma scale is also used by some authorsfor assessing xerostomia. Even though it is more specific,it is predominantly an observer based system and henceless frequently used.14
There is a significant correlation found between the postRT SEF and the mean parotid gland dose (p=0.0163)similar to Roesink et al.4 we also found significantcorrelation for SEF ratio and mean parotid gland dose atsix weeks (p = 0.003). Significance was also found at 12 -24 months after RT in several studies4, 5 probably, theacute functional impairment correlates with the latetoxicity implying the early changes are a predictor oflong term sequelae. Significant correlation between themean parotid gland dose and QOL scores (p = 0.04) wasfound in our study similar to Pow et al.6 who studiedxerostomia in nasopharyngeal cancer patients.No correlation was found between any scintigraphicparameter and QOL at six weeks. This might be becauseof the still dominant acute effects of radiation at sixweeks, more appropriate time to assess would bebeyond six months to one year.However,, interestinglyparotid gland sparing did not significantly improve drymouth in a study by Chen et al.5 indicating no correlationbetween the two. Even in other studies, using parotidflow rates to measure functional status of parotidglands, no significant correlation was found between theQOL scores and flow rates.6, 7, 8It is interesting to note that, though the other scoresrecovered at two years follow up, the dry mouthremained the same from completion of therapy eventhough it did not impact on overall QOL score, which issimilar to the study done by Benjamin et al. 9 andRingash et al.15The chief merit of our prospective study is that weanalyzed not only the subjectively using QOLQuestionnaire and objectively using scintigraphy butalso correlated them with DVH parameters. This enablesus to understand the variables and complex interactionsthat interplay in causing radiation toxicity and to deliverbetter healthcare to the patients. The major limitation ofour study is the restricted sample size and noscintigraphic assessment at two years follow up.Another scintigraphic assessment at two years wouldhave provided a better understanding of parotid glandrecovery.
5. ConclusionComprehensive assessment of parotid gland functionwith Scintigraphy, QOL questionnaire and its correlationwith DVH parameters is helpful in quantifyingxerostomia. Even though radiation induced xerostomiapersisted for a long time after radiation, it did nottranslate to decreased QOL. The dose received by theparotid glands has a direct correlation with xerostomia,hence efforts to reduce the dose to parotid by IMRTprobably further reduces dryness which may improveQOL
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